$58.02
2.13% yesterday
Nasdaq, Nov 06, 10:12 pm CET
ISIN
US2521311074
Symbol
DXCM

DexCom, Inc. Stock price

$58.02
-8.34 12.57% 1M
-23.51 28.84% 6M
-19.75 25.40% YTD
-10.59 15.44% 1Y
-57.31 49.69% 3Y
-32.31 35.77% 5Y
+36.84 173.94% 10Y
+54.75 1,671.60% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-1.26 2.13%
ISIN
US2521311074
Symbol
DXCM

New AI Insights on DexCom, Inc. Insights AI Insights on DexCom, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$22.6b
Enterprise Value
$21.8b
Net debt
positive
Cash
$3.3b
Shares outstanding
390.0m
Valuation (TTM | estimate)
P/E
32.8 | 27.6
P/S
5.0 | 4.8
EV/Sales
4.8 | 4.6
EV/FCF
20.5
P/B
8.3
Financial Health
Equity Ratio
32.4%
Return on Equity
27.4%
ROCE
18.7%
ROIC
15.7%
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$4.5b | $4.7b
EBITDA
$1.0b | $1.4b
EBIT
$777.7m | $972.7m
Net Income
$720.7m | $821.0m
Free Cash Flow
$1.1b
Growth (TTM | estimate)
Revenue
14.2% | 17.4%
EBITDA
21.6% | 57.3%
EBIT
23.8% | 48.8%
Net Income
5.9% | 42.5%
Free Cash Flow
98.5%
Margin (TTM | estimate)
Gross
60.2%
EBITDA
22.6% | 28.9%
EBIT
17.2%
Net
16.0% | 17.3%
Free Cash Flow
23.5%
More
EPS
$1.8
FCF per Share
$2.7
Short interest
3.8%
Employees
10k
Rev per Employee
$390.0k
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a DexCom, Inc. forecast:

30x Buy
83%
6x Hold
17%

Analyst Opinions

36 Analysts have issued a DexCom, Inc. forecast:

Buy
83%
Hold
17%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,516 4,516
14% 14%
100%
- Direct Costs 1,797 1,797
20% 20%
40%
2,719 2,719
11% 11%
60%
- Selling and Administrative Expenses 1,297 1,297
3% 3%
29%
- Research and Development Expense 590 590
8% 8%
13%
1,022 1,022
22% 22%
23%
- Depreciation and Amortization 244 244
15% 15%
5%
EBIT (Operating Income) EBIT 778 778
24% 24%
17%
Net Profit 721 721
6% 6%
16%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Neutral
Business Wire
about 8 hours ago
MONTREAL--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (I...
Positive
MarketBeat
about 19 hours ago
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature businesses, exhibiting fairly steady performance from quarter to quarter.
Neutral
PRNewsWire
3 days ago
NEW YORK , Nov. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 10,250
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today